You might be interested in the technology specifications in this Canadian funding call, where they obviously thought quite a lot about characteristics. Is anyone working on local magnetic bead protocols?
COVID-19 Challenge: Magnetic reagents for detection of COVID-19 and other RNA based molecular diagnostic kits
Essential (mandatory) outcomes
The solution must:
- Demonstrate a method for reagents formulation that is scalable and rapidly adaptable/customizable for different viral threats.
- As an immediate test case, demonstrate high specificity for COVID-19 RNA extraction.
- Be compatible with most clinical sample types (saliva, sputum, blood, swab, urine, as well as anycell-free media).
- Possess the ability to isolate and purify 1 copy/µL or less of viral RNA.
- Be rapid, within 15 minutes or less, and require a minimum number of manipulation steps to arrive at final solution.
- Introduce a complete solution, including lysis, extraction, washing, and elution into appropriate buffer.
- Integrate with downstream molecular diagnostics including RT-qPCR.
- Be compatible with most RT-qPCR reagents and buffers.
- Provide high extraction efficiencies without leading to false negatives, and be superior to gold standard spin-column methods.
- Provide high quality SARS-CoV-2 RNA preps for diagnostic use – devoid of any protein, lipid or other contaminants.
- Be customizable to microfluidic platforms for medical device sample-to-answer and sample preparation systems – in particular formulation that can be stored in dry and/or liquid formats in microfluidic polymer cartridges without losing efficacy.
- Be compatible with magnetic bead-based automated and high throughput applications.
- Integrate seamlessly with most robotic automated systems such as Thermo KingFisher, PerkinElmer Chemagic, and Roche MagNA Pure.
- Provide enough fabrication capacity of reagents that can feed fabrication of up to 100 000 tests /month. The reagents formulation must be compatible with room temperature storage for up to 6 months allowing for clinical deployment in distributed testing sites.
- Demonstrate, at the end of Phase 2, clinical efficacy data derived from a clinical trial comparing the buffer/reagents to the performance of the current gold standard for COVID-19 viral RNA extraction for downstream RT-qPCR. The gold standard is spin-column based kits, as well as other magnetic-based kits from well-known suppliers such as Qiagen, ThermoFisher, and Roche. Gold standard testing can be performed by the NRC or an accredited lab provided the samples are submitted in a blinded and anonimised fashion.
- Trial design should follow a non-inferiority trial design.
- Be amenable to scale-up manufacturing and not be hindered by foreign supply chain issues.